Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma

Abstract

AbstractBackgroundWith the increasing use of daratumumab (DARA)‐containing regimens for multiple myeloma (MM) patients in China, the standard infusion time of DARA is long, with the potential for infusion‐related reactions (IRRs) and increased hospitalization and use of resources. Shortening the duration of DARA infusion helps to optimize the hospital stay and enhance the patient treatment experience. The current, commonly used 90‐min rapid DARA infusion regimen may not be applicable to Chinese MM patients, and therefore, we explored a new 110‐min rapid DARA infusion regimen aimed at reducing the treatment burden on patients to guarantee therapeutic safety.MethodsMM inpatients treated with the DARA regimen were divided into two groups according to the number of times the DARA regimen was used: a standard infusion regimen for patients treated with the first two doses of DARA and a 110‐min rapid infusion regimen for patients treated with more than two doses of DARA. Anti‐allergy medications were routinely administered prior to the start of DARA infusion, patient consent, and authorization was obtained for all treatments, and statistical evaluation of the results was conducted via descriptive analyses, one‐way ANOVA and chi‐square tests.ResultsA total of 129 patients were included in this study: 68 in the standard infusion group, with 121 DARA infusions, and 129 in the rapid infusion group (patients who participated in the standard infusion subsequently participated in the rapid infusion), with 738 DARA infusions. The incidence of IRRs was 27.27% (36/121) in the standard infusion group and 1.35% (10/738) in the rapid infusion group, which were significantly different (p < 0.001). The incidence of IRRs after rapid infusion in other studies was <6%. The incidence of grade 1 IRRs in the rapid infusion group was 0.81% (6/738), the incidence of grade 2 IRRs was 0.54% (4/738), and there were no IRRs above grade 3; age, sex, and underlying disease had no effect on the choice of infusion method (p > 0.05). The mean infusion time after the occurrence of IRRs was also shorter in the rapid infusion group than in the standard infusion group (F = 24.781, p < 0.001).ConclusionThe 110‐min rapid infusion DARA regimen is feasible and safe for use in Chinese MM patients.